Dr Luke Gaughan, Northern Institute for Cancer Research at Newcastle University
Dr Luke Gaughan received a PCR Project Award.
Hormone Therapy: Stopping resistance in its tracks
Hormone therapy works by stopping a protein called the androgen receptor (AR) from telling cancer cells to grow. Normally the AR exists in two parts, with the outside part like a switch that needs to be turned on by male hormones, so that the inside part can help the cancer to grow and spread. On normal AR, drugs can turn that switch off. But sometimes different versions of the AR, called AR variants, or ARVs, are made. ARVs are cut-off versions of the AR which don’t have a switch to turn on or off, but are always on. They exist in about 95% of prostate cancers which have spread, and hormone therapy doesn’t work on them.
This team have developed cutting-edge technology to give powerful insights into how ARVs are made in advanced prostate cancer cells. They will find out how ARVs are made, and how this process could be stopped.
The Scientist Said...
“Together with my co-leads on the PCR-funded project Mr Rakesh Heer, Consultant Urological Surgeon, and Prof Craig Robson, we will be undertaking a super novel approach to study how we can prevent advanced prostate cancer-associated forms of the androgen receptor being generated. By blocking this process we will be able to prevent disease progression. We are thrilled to be part of the national PCR research team and are very much looking forward to helping deliver new targets for future treatments to help men with prostate cancer.” – Luke Gaughan